# Title

 Food and Drugs. PART 25â€”ENVIRONMENTAL IMPACT CONSIDERATIONS


# ID

 CFR-2018-title21-vol1.Pt. 25


# Structured Analysis Summary

| Type        | Values                                                                                                                                                                                                                                                               |
|:------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Constraints | ['before', 'more than', 'within', 'greater than', 'less than', 'after', 'at least']                                                                                                                                                                                  |
| Duration    | ['30.0 day']                                                                                                                                                                                                                                                         |
| Condition   | ['unless', 'where', 'if not', 'subject to', 'when', 'if']                                                                                                                                                                                                            |
| Entities    | ['United States', 'Lead', 'Agency', 'Rockville, MD', 'Endangered Species', 'Environmental', 'Tobacco', 'Animal', 'Scope', 'Issuance', 'Food', 'Council', 'Good', 'Human', 'Purpose', 'Foods', 'Failure', 'Fungicide', 'Public', 'Terminology', 'Appropriate', 'New'] |
| Date        | ['2018-02-04', '1980-11-19', '2018-02-03', '1957-01-09', '1979-01-04', '2018-02-05']                                                                                                                                                                                 |


# Structured Analysis With Context

 


## Constraints

| Constraints   | Context                                                                                                                      |
|:--------------|:-----------------------------------------------------------------------------------------------------------------------------|
| before        | official shall consult with CEQ about alternative arrangements before the action is taken, or after the action               |
| after         | alternative arrangements before the action is taken, or after the action is taken, if time does not                          |
| at least      | a type specified in this section normally requires at least the preparation of an EA, unless it is                           |
| after         | (b) Destruction or other disposition of articles condemned  after seizure or whose distribution or use has been              |
| at least      | required under 40 CFR 1508.4, FDA will require at least an EA for any specific action that ordinarily                        |
| after         | Destruction or disposition of any FDA-regulated article condemned after seizure or the distribution or use of which          |
| before        | space in a structure that was substantially completed before  the issuance of solicitation for offers; and                   |
| less than     | square feet of occupiable space if it constitutes less than 40 percent of the occupiable space in a                          |
| before        | space in a structure that was substantially completed before  the solicitation for offers.                                   |
| greater than  | is present in finished food-packaging material at not greater than 5 percent-by-weight and is expected to remain with        |
| more than     | If an action affects  more than one center within FDA, the Commissioner of Food                                              |
| within        | If an action affects more than one center  within FDA, the Commissioner of Food and Drugs will                               |
| before        | publicly available, the release of the environmental document before approval or authorization of human drugs, animal drugs, |
| before        | to complete environmental consideration of the proposed action before a notice of filing of a food or                        |
| before        | State and areawide information clearinghouses) for 30 days before the agency makes its final determination whether to        |
| before        | State and areawide information clearinghouses) for 30 days before the agency makes its final determination whether to        |
| after         | (b) Comments on the EIS may be submitted  after the approval or market authorization of the drug,                            |
| before        | devices, or tobacco products has already been disclosed before the Agency approves the action, the Agency will               |
| before        | actions may have a significant environmental effect abroad. before                                                           |


## Duration

| Duration   | Context                                                                                                                                                                                                                                                                                                                            |
|:-----------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 30.0 day   | (3) For a limited number of actions, the agency may make the FONSI and EA available for public review (including review by State and areawide information clearinghouses) for 30 days before the agency makes its final determination whether to prepare an EIS and before the action may begin, as described in 40 CFR 1501.4(e). |


## Condition

| Condition   | Context                                                                                                                                         |
|:------------|:------------------------------------------------------------------------------------------------------------------------------------------------|
| where       | the procedures in section 102(2) of NEPA except where  compliance would be inconsistent with other statutory requirements.                      |
| if          | of a drug or biologic product may occur if the drug will be administered at higher dosage                                                       |
| if          | of a drug or biologic product may occur if the drug will be administered at higher dosage                                                       |
| when        | by the agency, the NEPA process will begin when  the agency action under consideration is first identified.                                     |
| when        | initiated by applicants or petitioners, NEPA planning begins when FDA receives from an applicant or petitioner an                               |
| when        | initiated by applicants or petitioners, NEPA planning begins when FDA receives from an applicant or petitioner an                               |
| when        | or otherwise consult with affected individuals or groups when a contemplated action in which it is or                                           |
| if          | HHS General Administration Manual, part 30: Environmental Protection. if                                                                        |
| unless      | the agency of a type specified in &#167;&#8201;25.20, unless the agency can determine that the action qualifies                                 |
| subject to  | submitting an application or petition of a type subject to categorical exclusion under &#167;&#167;&#8201;25.30, 25.31, 25.32, 25.33, 25.34,    |
| if          | 25.32(h), is not required to submit an EA if  the person states that the action requested qual                                                  |
| if          | is taken, or after the action is taken, if  time does not permit prior consultation with CEQ.                                                   |
| unless      | requires at least the preparation of an EA, unless it is an action in a specific class                                                          |
| where       | to Congress on proposals for legislation in instances where the agency has primary responsibility for the subject                               |
| unless      | or whose distribution or use has been enjoined, unless  categorically excluded in &#167;&#167;&#8201;25.30(d) or 25.32(h).                      |
| unless      | articles following detention or recall at agency request, unless  categorically excluded in &#167;&#167;&#8201;25.30(d) or 25.32(h).            |
| unless      | (d) Disposition of FDA laboratory waste materials,  unless  categorically excluded in &#167;&#8201;25.30(m).                                    |
| unless      | in part through contracts, other agreements, or grants, unless  categorically excluded in &#167;&#8201;25.30 (e) or (f).                        |
| unless      | of labeling requirements, a standard, or a monograph, unless categorically excluded in &#167;&#167;&#8201;25.30(k) or 25.31 (a), (b),           |
| unless      | or an exemption or variance from FDA regulations, unless categorically excluded in &#167;&#8201;25.30 (h), (i), or (j),                         |
| unless      | (h) Withdrawal of existing approvals of FDA-approved articles,  unless categorically excluded in &#167;&#167;&#8201;25.31 (d) or (k), 25.32(m), |
| unless      | submitted under 21 U.S.C. 348(h) to become effective, unless categorically excluded in &#167;&#8201;25.32(b), (c), (i), (j), (k),               |
| unless      | defined in &#167;&#167;&#8201;170.3(l) and 181.5(a) of this chapter, unless categorically excluded in &#167;&#8201;25.32(f), (i), (j), (k), or  |
| unless      | supplements to such applications, and actions on IND's, unless categorically excluded in &#167;&#8201;25.31 (a), (b), (c), (e),                 |
| unless      | of requests for determination of eligibility for indexing, unless categorically excluded under &#167;&#8201;25.33 (a), (c), (d), or             |
| unless      | an approved PDP, or applications for an IDE, unless  categorically excluded in &#167;&#8201;25.34.                                              |
| unless      | 1107 from the requirement of demonstrating substantial equivalence, unless  categorically excluded under &#167;&#8201;25.35.                    |
| unless      | of the Federal Food, Drug, and Cosmetic Act, unless  categorically excluded under &#167;&#8201;25.35.                                           |
| if          | require at least an EA for any spec if ic action that ordinarily would be excluded                                                              |
| when        | (b) EIS's are prepared for agency actions  when evaluation of data or information in an EA                                                      |
| if          | or following detention or recall at agency request if the method of destruction or disposition of the                                           |
| if          | by regulation of labeling requirements for marketed articles if there will be no increase in the existing                                       |
| if          | feet and 40,000 square feet of occupiable space if it constitutes less than 40 percent of the                                                   |
| if          | laboratories serviced by the contracts administered by FDA, if the waste is disposed of in compliance with                                      |
| if          | such applications, or action on an OTC monograph, if the action does not increase the use of                                                    |
| if          | such applications, or action on an OTC monograph, if the action increases the use of the active                                                 |
| when        | for substances that occur naturally in the environment when the action does not alter significantly the concentration                           |
| subject to  | or a comparability determination for a biologic product subject to  licensing.                                                                  |
| if          | exemption for investigational use of a food additive if the food additive to be shipped under the                                               |
| if          | defined in &#167;&#167;&#8201;170.3(l) and 181.5(a) of this chapter, if the substance or food ingredient is already marketed                    |
| when        | submitted under 21 U.S.C. 348(h) to become effective, when the substance is present in finished food-packaging material                         |
| when        | submitted under 21 U.S.C. 348(h) to become effective, when the substance is present in finished food-packaging material                         |
| when        | submitted under 21 U.S.C. 348(h) to become effective, when the substance is to be used as a                                                     |
| when        | a substance that occurs naturally in the environment, when the action does not alter significantly the concentration                            |
| if          | a supplement to such applications, or a mod if ication of an index listing,                                                                     |
| if          | a previously approved animal drug; (4) Changes spec if ied in &#167;&#8201;514.8(b)(3), (b)(4), or (c)(3) of this                               |
| when        | for substances that occur naturally in the environment when the action does not alter significantly the concentration                           |
| when        | for minor species, including wildlife and endangered species, when the drug has been previously approved for use                                |
| where       | for use in another or the same species where similar animal management practices are used; and (5)                                              |
| if          | (b) Class if ication or reclass                                                                                                                 |
| if          | or notices for a class III medical device if the device is of the same type and                                                                 |
| if          | (f) Issuance of a restricted device regulation  if it will not result in increases in the                                                       |
| when        | testing approach, in which testing may be stopped when the results suggest that no significant impact will                                      |
| when        | and may include additional information in environmental documents when  warranted.                                                              |
| if          | (2) Any adverse effects that cannot be avoided if the action is implemented; (3) Alternatives to the                                            |
| if not      | or minimize environmental harm have been adopted, and if not , why not; and (4) Summarize the program                                           |
| unless      | Therefore,  unless the existence of applications for human drugs, animal                                                                        |
| when        | public inspection at FDA's Division of Dockets Management. when                                                                                 |
| if          | required to be published under the act, and if the subsequent environmental analysis leads to the conclusion                                    |
| when        | This procedure will be followed  when the proposed action is, or is closely similar                                                             |
| when        | This procedure will be followed  when the proposed action is, or is closely similar                                                             |
| if          | the approval or market authorization of the product. if                                                                                         |
| where       | (c) In those cases  where the existence of applications and premarket notifications for                                                         |
| if          | determines that an action may have a sign if icant environmental effect abroad, the responsible agency official                                 |
| subject to  | of the Executive Order, whether proposed actions are subject to the exemptions, exclusions, and modification in contents, timing,               |


## Entities

| Entities           | Context                                                                                                                  |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------|
| Food               | Food  and Drugs.                                                                                                         |
| Purpose            | Purpose .                                                                                                                |
| United States      | the policies, regulations, and public laws of the United States shall be interpreted and administered in accordance with |
| Terminology        | Terminology .                                                                                                            |
| Scope              | (18)  Scope  (40 CFR 1508.25).                                                                                           |
| Council            | acronyms are used in this part: (1) CEQ&#8212; Council  on Environmental Quality.                                        |
| Fungicide          | (6) FIFRA&#8212;Federal Insecticide,  Fungicide , and Rodenticide Act.                                                   |
| Good               | (8) GLP&#8212; Good  laboratory practice.                                                                                |
| New                | (14) NADA&#8212; New  animal drug application.                                                                           |
| New                | (15) NDA&#8212; New  drug application.                                                                                   |
| Failure            | Failure to submit an adequate EA for an application                                                                      |
| Public             | Public  health and safety emergencies.                                                                                   |
| Issuance           | (g)  Issuance , amendment, and enforcement of FDA regulations, or                                                        |
| Endangered Species | critical habitat of a species determined under the Endangered Species  Act or the Convention on International Trade in   |
| Issuance           | (h)  Issuance , amendment, or revocation of procedural or administrative                                                 |
| Human              | Human  drugs and biologics.                                                                                              |
| Issuance           | (h)  Issuance , revocation, or amendment of a standard for                                                               |
| Foods              | Foods , food additives, and color additives.                                                                             |
| United States      | or food ingredient is already marketed in the United States  for the proposed use.                                       |
| Issuance           | (n)  Issuance , amendment, or revocation of a regulation pertaining                                                      |
| Issuance           | (p)  Issuance , amendment, or revocation of a regulation in                                                              |
| Animal             | Animal  drugs.                                                                                                           |
| Issuance           | (c)  Issuance , amendment, or repeal of a standard for                                                                   |
| Tobacco            | Tobacco  product applications.                                                                                           |
| Environmental      | Environmental  assessments.                                                                                              |
| Environmental      | Environmental  impact statements.                                                                                        |
| Lead               | Lead  and cooperating agencies.                                                                                          |
| Food               | than one center within FDA, the Commissioner of Food and Drugs will designate one of these units                         |
| Appropriate        | Appropriate environmental documents, comments, and responses will be included                                            |
| Environmental      | Environmental  assessments and findings of no significant impact.                                                        |
| Environmental      | Environmental  impact statements.                                                                                        |
| Agency             | Those comments can form the basis for the  Agency to consider beginning an action to withdraw the                        |
| Rockville, MD      | 1061,  Rockville, MD  20852.                                                                                             |
| Environmental      | Environmental  effects abroad of major agency actions.                                                                   |
| United States      | export of products (or emissions) that in the United States are prohibited or strictly regulated because their effects   |


## Date

| Date       | Context                                                                                                                                                                                                                                                                                                                                                            |
|:-----------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1980-11-19 | This part also supplements the regulations for implementing the procedural provisions of NEPA that were published by the Council on Environmental Quality (CEQ) in 40 CFR parts 1500 through 1508 and the procedures included in the &#8220;HHS General Administration Manual, part 30: Environmental Protection&#8221; (45 FR 76519 to 76534, November 19, 1980). |
| 1979-01-04 | (a) In accordance with Executive Order 12114, &#8220;Environmental Effects Abroad of Major Federal Actions&#8221; of January 4, 1979 (44 FR 1957, January 9, 1979), the responsible agency official, in analyzing actions under his or her program, shall consider the environmental effects abroad, including whether the actions involve:                        |
|            |               (1) Potential environmental effects on the global commons and areas outside the jurisdiction of any nation, e.g., oceans and the upper atmosphere.                                                                                                                                                                                                   |
| 1957-01-09 | (a) In accordance with Executive Order 12114, &#8220;Environmental Effects Abroad of Major Federal Actions&#8221; of January 4, 1979 (44 FR 1957, January 9, 1979), the responsible agency official, in analyzing actions under his or her program, shall consider the environmental effects abroad, including whether the actions involve:                        |
|            |               (1) Potential environmental effects on the global commons and areas outside the jurisdiction of any nation, e.g., oceans and the upper atmosphere.                                                                                                                                                                                                   |
| 2018-02-03 | (b) Before deciding on any action falling into the categories specified in paragraph (a) of this section, the responsible agency official shall determine, in accordance with section 2-3 of the Executive Order, whether such actions may have a significant environmental effect abroad.                                                                         |
| 2018-02-04 | (c) If the responsible agency official determines that an action may have a significant environmental effect abroad, the responsible agency official shall determine, in accordance with section 2-4 (a) and (b) of the Executive Order, whether the subject action calls for:                                                                                     |
|            |               (1) An EIS;                                                                                                                                                                                                                                                                                                                                          |
|            |               (2) A bilateral or multilateral environmental study; or                                                                                                                                                                                                                                                                                              |
|            |               (3) A concise environmental review.                                                                                                                                                                                                                                                                                                                  |
| 2018-02-05 | (1) Determine, as provided in section 2-5 of the Executive Order, whether proposed actions are subject to the exemptions, exclusions, and modification in contents, timing, and availability of documents.                                                                                                                                                         |


